US biotech firm Guardant Well being (Nasdaq: GH) has acquired Israeli exact liquid biopsy firm MetaSight Diagnostics for a right away fee of $59 million and a further $90 million in milestone funds. The acquisition was revealed in Guardant Well being’s fourth quarter outcomes. The milestone funds embody receiving regulatory approvals and gross sales thresholds. The corporate has developed exams for correct early analysis of most cancers that might price just a few {dollars}.
MetaSight was based by Prof. Tomer Shlomi from the Technion along with aMoon Fund as a part of the aMoon Velocity program. The corporate makes use of multiomics applied sciences, to research cells utilizing totally different approaches, and mixing data with AI, to diagnose colon most cancers and metabolic issues in liver perform. The expertise is within the scientific trial stage.
The corporate developed the expertise based mostly on the Maccabi Well being Fund database.
The exit is modest however offers quick and good-looking returns for aMoon.. MetaSight was based in 2020 and has raised $20 million to this point. Amongst its traders are the US fund ARC and Saban Ventures. The corporate has workplaces in Rehovot that may develop into Guardant’s first improvement web site in Israel.
Dr. Yaron Daniely, who leads the aMoon Velocity program, tells “Globes,” “Guardant is a number one firm within the subject of most cancers analysis utilizing superior strategies. Their market worth is about $13.7 billion and so they recorded income of a couple of billion {dollars} this 12 months.”
Discovered a typical language
How did the connection with the corporate come about?
“Guardant acknowledged the corporate’s benefits after we introduced our exams at conferences that allow speedy analysis at costs of some {dollars} per take a look at. They talked about of their convention name that they’d reviewed dozens of firms within the subject and selected our expertise from them.”
“We additionally selected them,” provides Dr. Daniely, “We acquired inquiries from a number of firms. With Guardant, we discovered widespread floor. The corporate’s cofounders and co-CEOs Helmy Eltoukhy and AmirAli Talasaz, are former Iranians, so there was a cultural connection between us. They based the corporate in 2012 and nonetheless function it with an entrepreneurial method. They enormously worth the corporate’s workers in Israel, and for the reason that acquisition, they’ve employed workers and expanded the laboratory. That is their first improvement heart not solely in Israel, however that is the primary time they’ve exterior the US.”
Nevertheless, Danieli says with a smile: “That does not imply that the negotiations have been straightforward.”
How was the corporate based?
“Prof. Shlomi approached us after growing a technique to considerably scale back the price and pace up diagnostics utilizing a mass spectrometer. This methodology allowed us to diagnose samples at very excessive resolutions. We teamed up with Maccabi and created a database of almost one million samples coded utilizing the MetaSight methodology. Based mostly on this, we developed the colon most cancers take a look at.
“The take a look at is about two to 3 years away from finishing scientific trials, and if these are profitable, then the extra quantity can be paid within the deal.”
Revealed by Globes, Israel enterprise information – en.globes.co.il – on February 21, 2026.
© Copyright of Globes Writer Itonut (1983) Ltd., 2026.
